Beijing Scitop Bio-tech Co., Ltd. (SHE:300858)

Market Cap	4.40B +21.3%
Revenue (ttm)	351.47M +16.8%
Net Income	99.40M +7.3%
EPS	0.38 +8.6%
Shares Out	263.50M
PE Ratio	43.88
Forward PE	26.48
Dividend	0.15 (0.91%)
Ex-Dividend Date	Jul 16, 2025

Volume	3,205,831
Average Volume	3,849,378
Open	16.45
Previous Close	16.41
Day's Range	16.33 - 16.77
52-Week Range	11.03 - 24.66
Beta	0.58
RSI	35.04
Earnings Date	Apr 22, 2026

About Beijing Scitop Bio-tech

Beijing Scitop Bio-tech Co., Ltd. researches, develops, produces, and sells probiotic, postbiotics, and microecologival preparations for animals and plants in China. It provides probiotic and postbiotics for gastrointestinal health, immune regulation, oral health, sleep aid and stress relief, women’s health, slimming and fat reduction, kidney and liver protection, blood sugar regulation, allergy relief, blood pressure regulation, and mother-infant transmission, as well as exercise, bone, heart, and skin health applications. The company also off...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2003
• Employees: 295
• Stock Exchange: Shenzhen Stock Exchange
• Ticker Symbol: 300858

Financial Performance

In 2024, Beijing Scitop Bio-tech's revenue was 302.79 million, an increase of 1.19% compared to the previous year's 299.24 million. Earnings were 94.36 million, an increase of 0.94%.